Hambardzumyan K, et al. - Through a Swedish pharmacotherapy (SWEFOT) clinical trial, the investigators sought to understand the response to methotrexate (MTX) in patients with early rheumatoid arthritis (eRA) in order to understand the baseline levels of 12 serum bio-markers that constitute a multi-bio-marker disease activity test. Decreased chance of low disease activity (LDA) was associated with combined score based on bio-markers. Four of the 12 bio-markers, C-reactive protein (CRP), leptin, tumor necrosis factor receptor I (TNF-RI), and vascular cell adhesion molecule 1 (VCAM-1) were remarkably noticed, Three months post methotrexate mono-therapy in patients with eRA, CRP and leptin at low baseline levels and TNF-RI and VCAM-1 at high baseline levels were associated with LDA. While, all 4 bio-markers combined, increased predictability.